Recombinant Interleukin-11
Cross-source consensus on Recombinant Interleukin-11 from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- Recombinant interleukin-11 was the strongest adjusted atrial fibrillation reporting signal in the study. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- Recombinant interleukin-11 is used to prevent or treat chemotherapy-induced thrombocytopenia. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- The rIL-11 signal remained significant after adjustment for indication. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- Clinical trial evidence cited in the article found a higher incidence of atrial fibrillation or atrial flutter with recombinant interleukin-11 than placebo. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- Several case features strengthened concern for a possible causal association between recombinant interleukin-11 and atrial fibrillation reporting. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- IL-11 can promote profibrotic effects by stimulating cardiac fibroblasts through ERK pathway activity at physiological levels. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review